COMP <GO>
LIVN vs TMDX // RSI-14 & 200D SMA MOMENTUM
LivaNova PLC (NASDAQ) VS. TransMedics Group Inc. (NASDAQ) • 15-METRIC TALLY: LIVN 3
— TMDX 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LIVN
LAST: $81.25 (+0.73%) • MKT CAP: $4.48B
rsi-technicals
58.2
LAST: $67.12 (+0.33%) • MKT CAP: $2.33B
rsi-technicals
32.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LIVN VS. TMDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LIVN | TMDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.70% | 59.90% | +7.80 | LIVN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.30% | 18.10% | -0.80 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.6x | 14.6x | +1.00 | TMDX | /valuation <GO> |
| Free Cash Flow Yield | 3.87% | 5.74% | -1.87 | TMDX | /fcf-yield <GO> |
| Operating Margin | 14.40% | 17.90% | -3.50 | TMDX | /operating-margins <GO> |
| Net Profit Margin | -17.50% | 31.40% | -48.90 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 10.70% | 37.10% | -26.40 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 3.50 | -1.29 | TMDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 58.2 | 32.5 | +25.70 | LIVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.48B | $2.33B | $2.15B | LIVN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LIVN REV | TMDX REV | LIVN GROSS % | TMDX GROSS % | LIVN FCF | TMDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.39B | $605.5M | 67.7% | 59.9% | $173.3M | $133.6M |
| FY 2024 | $1.25B | $441.5M | 68.1% | 59.4% | $135.9M | -$80.9M |
| FY 2023 | $1.15B | $241.6M | — | — | $74.9M | -$13.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LIVN // BETA —
TMDX // BETA —